| Followers | 0 |
| Posts | 3251 |
| Boards Moderated | 0 |
| Alias Born | 04/21/2025 |
Sunday, July 13, 2025 9:07:12 AM
They offered 4 million shares at $5 in 2001
Prior to that there were only 23 million shares outstanding.
So 27 million shares total outstanding in 2001 at $5. Or $135 Million Mkt Cap.
Since then they did 2 reverse splits, decimating shareholders as the stock tanked both times subsequently.
Northwest Biotherapeutics has conducted two reverse stock splits in its history: one on June 28, 2007, and another on September 26, 2012. The cumulative effect of these splits is a 1:240 reverse split, meaning that 240 shares before the first split would be equivalent to 1 share today.
The bottom line is that if you invested $1,200.00 in 2001 , your investment is worth $0.22 cents today.
If you invested $12,000.00 your investment is worth $2.20 today , that's Two Dollars and 20 cents left in your account, total on a $12,000.00 investment.
Prior to that there were only 23 million shares outstanding.
So 27 million shares total outstanding in 2001 at $5. Or $135 Million Mkt Cap.
Since then they did 2 reverse splits, decimating shareholders as the stock tanked both times subsequently.
Northwest Biotherapeutics has conducted two reverse stock splits in its history: one on June 28, 2007, and another on September 26, 2012. The cumulative effect of these splits is a 1:240 reverse split, meaning that 240 shares before the first split would be equivalent to 1 share today.
The bottom line is that if you invested $1,200.00 in 2001 , your investment is worth $0.22 cents today.
If you invested $12,000.00 your investment is worth $2.20 today , that's Two Dollars and 20 cents left in your account, total on a $12,000.00 investment.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
